Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality by Čiginskienė, Aušra et al.
medicina
Article
Ventilator-Associated Pneumonia due to
Drug-Resistant Acinetobacter baumannii: Risk Factors
and Mortality Relation with Resistance Profiles, and
Independent Predictors of In-Hospital Mortality
Aušra Cˇiginskiene˙ 1,*, Asta Dambrauskiene˙ 2, Jordi Rello 3,4,5,6,7 and Dalia Adukauskiene˙ 1,*
1 Department of Intensive Care, Medical Academy, Lithuanian University of Health Sciences,
50161 Kaunas, Lithuania
2 Infection Control Service, Medical Academy, Lithuanian University of Health Science, 50161 Kaunas,
Lithuania; dambrauskienea@gmail.com
3 Department of Intensive Care, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; jrello@crips.es
4 CIBERES, 08035 Barcelona, Spain
5 Universitat Autonoma de Barcelona, 08193 Barcelona, Spain
6 Vall d’Hebron Institute of Research, 08035 Barcelona, Spain
7 CRIPS, Vall d’Hebron Institute of Research (VHIR), 08035 Barcelona, Spain
* Correspondence: ausraciginskiene@yahoo.com (A.Cˇ.); daliaadu@gmail.com (D.A.);
Tel.: +37037326425 (A.Cˇ.); +370 37 326425 (D.A.)
Received: 15 December 2018; Accepted: 7 February 2019; Published: 13 February 2019


Abstract: Background and objectives: High mortality and healthcare costs area associated with
ventilator-associated pneumonia (VAP) due to Acinetobacter baumannii (A. baumannii). The data
concerning the link between multidrug-resistance of A. baumannii strains and outcomes remains
controversial. Therefore, we aimed to identify the relation of risk factors for ventilator-associated
pneumonia (VAP) and mortality with the drug resistance profiles of Acinetobacter baumannii
(A. baumannii) and independent predictors of in-hospital mortality. Methods: A retrospective
ongoing cohort study of 60 patients that were treated for VAP due to drug-resistant A. baumannii
in medical-surgical intensive care units (ICU) over a two-year period was conducted. Results:
The proportions of multidrug-resistant (MDR), extensively drug-resistant (XDR), and potentially
pandrug-resistant (pPDR) A. baumannii were 13.3%, 68.3%, and 18.3%, respectively. The SAPS II scores
on ICU admission were 42.6, 48.7, and 49 (p = 0.048); hospital length of stay (LOS) prior to ICU was 0,
one, and two days (p = 0.036), prior to mechanical ventilation (MV)—0, 0, and three days (p = 0.013),
and carbapenem use prior to VAP—50%, 29.3%, and 18.2% (p = 0.036), respectively. The overall
in-hospital mortality rate was 63.3%. In MDR, XDR, and pPDR A. baumannii VAP groups, it was 62.5%,
61.3%, and 72.7% (p = 0.772), respectively. Binary logistic regression analysis showed that female
gender (95% OR 5.26; CI: 1.21–22.83), SOFA score on ICU admission (95% OR 1.28; CI: 1.06–1.53), and
RBC transfusion (95% OR 5.98; CI: 1.41–25.27) were all independent predictors of in-hospital mortality.
Conclusions: The VAP risk factors: higher SAPS II score, increased hospital LOS prior to ICU, and
MV were related to the higher resistance profile of A. baumannii. Carbapenem use was found to be
associated with the risk of MDR A. baumannii VAP. Mortality due to drug-resistant A. baumannii VAP
was high, but it was not associated with the A. baumannii resistance profile. Female gender, SOFA
score, and RBC transfusion were found to be independent predictors of in-hospital mortality.
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1. Introduction
Ventilator-associated pneumonia (VAP) is one of the most common intensive care unit
(ICU)-acquired infections that are associated with a prolonged duration of antibacterial treatment,
length of hospital stay (LOS), and mechanical ventilation (MV), as well as high mortality and
healthcare costs [1–4]. Acinetobacter baumannii (A. baumannii) is one of the most prevalent VAP-causing
pathogens [3,5,6]. The incidence of VAP due to Acinetobacter spp. varies across different goegraphic
regions [7]. Although infections due to Acinetobacter spp. were originally thought to be associated
with humid climates, in recent decades, this infection has also rapidly spread in temperate climates [8].
Acinetobacter is an obligate aerobic nonfermenting gram-negative nonmotile bacterium that
was discovered by Dutch microbiologist Martinus Willem Beigerinck in 1911 [9]. For a long time,
Acinetobacter was considered to be bacteria of low virulence, being susceptible to commonly used
antibacterial agents, but since the 1970s its resistance began to increase and then became a serious
problem, especially in nosocomial settings [4,9]. Nowadays, infections that are due to A. baumannii
are recognized to be one of the most threatening and are difficult to control and to treat in critical care
settings [3–5,10–12]. A. baumannii survives equally in both dry and humid environments, is resistant
to disinfectants and ultimate drying, and is able to form biofilms that facilitate bacterial bonding
to tissues, also various environmental surfaces, devices, and quickly acquiring various antibiotic
resistance mechanisms [8]. It is believed that these properties have led to the rapid endemic spread
of A. baumannii in the hospital environment and many ICUs worldwide, particularly within Europe.
In 2015, the European antimicrobial resistance surveillance network report stated that the share of
drug-resistant A. baumannii strains across Europe was steadily increasing [13]. The highest levels of
A. baumannii drug resistance were observed in Southern and Southeastern Europe and in the Baltic
States, especially within Lithuania. In 2017, A. baumannii was included in the WHO global priority list
of drug-resistant bacteria in order to highlight the need for research development and the urgency for
new antibiotics [14]. According to the data of the Lithuanian Center for Communicable Diseases and
AIDS, the rate of VAP in Lithuania has increased from 15.9 to 30.3 cases per 1000 mechanical ventilation
days in the period of 2014–2017 [15,16]. A. baumannii was identified as the most common causative
agent of VAP [15]. The drug resistance of A. baumannii strains increased by 21% in carbapenems and
aminoglycosides, and by 25.9% in fluoroquinolones in the period of 2014–2017 in Lithuania [17].
Treatment of infections due to A. baumannii remains challenging. High rates of native resistance,
as well as the rapid increase of acquired resistance to commonly prescribed antibiotics classes
limits the choice of active antibacterial treatment and compromises the course of disease and
patient’s outcomes. Historically, imipenem therapy was the “gold standard for pneumonia due
to A. baumannii [18]. Later, the selection of empirical treatment was recommended, depending
on the time of onset of VAP and the presence of risk factors for resistant microorganisms [1].
For patients with late-onset disease or risk factors for multidrug-resistant pathogen combination
antibiotic therapy (antipseudomonal cephalosporin or carbapenem or ß-lactam/ß-lactamase inhibitor
plus antipseudomonal fluoroquinolone or aminoglycoside) was recommended [1]. Due to the progress
of antibacterial resistance, alternative options were scant; therefore, it has led to a return to the old, less
effective, and more toxic polymyxins and tetracyclines, for which this bacterium still remains sensitive.
Often, colistin is the last-resort medicine, despite nephrotoxicity and neurotoxicity; poor penetration to
the lung tissue also continues to limit its’ use in VAP treatment. Moreover, resistance to the last-choice
colistin has also gained a threatening spread in recent years [4]. Therefore, if high drug resistance of
A. baumannii is prevalent in a hospital or departments, empirical combined treatment with colistin
plus carbapenem, sulbactam, or tigecycline should be used.
Greater mortality and higher health care associated costs were found to be associated with the
delayed recognition and treatment of VAP due to drug-resistant A. baumannii [4]. Age, previous
hospitalizations, surgery, invasive monitoring and treatment procedures, and comorbidities were
identified as risk factors for VAP [1]. Hospital LOS, previous antibacterial treatment, duration
of MV, disease severity, and prevalence of drug-resistant A. baumannii strains in hospitals in the
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community have also been recognized as risk factors namely for VAP due to multidrug-resistant
A. baumannii [1,2,19]. Unfortunately, there is no data regarding the relation between A. baumannii
resistance profiles (multidrug-resistant (MDR), extensively drug-resistant (XDR), and potentially
pandrug-resistant (pPDR)), and the risk factors of VAP as well as the patient outcomes in Lithuania that
are based on microbiological and clinical researches. Knowledge about the risk factors and mortality
association with different degrees of antibacterial resistance of A. baumannii, and the estimation of
mortality predictors of these patients are relevant for more rapid diagnosis, urgent treatment, and
they may influence the improvement of patients’ outcomes. It is unclear whether the results of the
studies that were conducted in other countries can be extrapolated to Lithuanian patients due to the
differences in regional healthcare systems as well as prevailing VAP pathogens and their mechanisms
of drug-resistance. The aim of our study was specifically to identify the relation of risk factors for
ventilator-associated pneumonia (VAP) and mortality with the resistance profiles of A. baumannii,
while also estimating the independent predictors of in-hospital mortality.
2. Materials and Methods
A retrospective cohort study of medical records of patients that were admitted to 18-bed
medical-surgical adult ICUs was conducted at Lithuania’s largest 2300-bed university-affiliated
hospital over a two-year period (from January 2014 to December 2015). Kaunas Regional Biomedical
Research Ethics Committee approved this study (No. BE-2-13). The need for written consent was
waived due to the retrospective nature of the study.
Inclusion criteria were as follows: (1) age ≥ 18 year, (2) the first episode of VAP due to
drug-resistant A. baumannii. Pneumonia was considered to be ventilator-associated when it occurred
after more than 48 h after the onset of mechanical ventilation. Clinical diagnosis of VAP was made
according to 2005 ATS/IDSA criteria [1]. Sepsis and septic shock were diagnosed according to Sepsis-2
criteria [20].
Data collected for each VAP case included age, gender, type of admission
(internal disease/surgical/trauma), hospital, and ICU LOS, MV prior to and after VAP diagnosis, and
antibacterial treatment days prior to VAP diagnosis, the presence of chronic illness (diabetes mellitus,
heart, neurologic and obstructive pulmonary disease, renal and hepatic failure, and malignancy),
sepsis status, drug resistance of A. baumannii isolates, history of antibiotics used, red blood cell (RBC)
transfusion, surgery, reintubation, tracheostomy, coma, and outcome (discharge or death). Mortality
included all deaths occurring during the hospital stay among patients with VAP due to drug-resistant
A. baumannii. Severity of illness was assessed on ICU admission while using the Sequential Organ
Failure Assessment (SOFA), Simplified Acute Physiology Score (SAPS) II, and Acute Physiology and
Chronic Health Evaluation (APACHE) II scores.
The identification of A. baumannii isolates and antibiotic susceptibility was performed according
to the EUCAST guidelines [21]. Drug-resistance profiles of A. baumannii were defined as MDR, XDR,
or potentially PDR (pPDR) according to an international expert proposal for the interim standard
definitions for acquired resistance criteria [22]. We decided to use the pPDR category of A. baumannii
resistance instead of PDR due to the incomplete testing of drug resistance in our hospital that was
performed until summer 2015 (testing to colistin was not used).
Statistics
The variables were summarized as frequencies and percentage, means and standard deviation,
or medians and interquartile ranges. The normality of data was tested using the Shapiro–Wilk
normality test. Student’s t test, Mann–Whitney non-parametric test, Pearson’s chi-square test,
two-tailed Fisher’s exact test, or Kruskal–Wallis test were performed to detect the differences between
groups as appropriate. All of the variables that were measured were subjected to univariate analyses.
Binary logistic regression analysis was applied to identify the independent predictors of in-hospital
mortality. A receiver operating characteristic (ROC) analysis was used to determine the area under the
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curve (AUC) and the cut-off values of SAPS II, APACHE II, and SOFA scores for predicting mortality.
In all analyses, two-sided p values of < 0.05 were considered to be statistically significant. Statistical
analysis was carried out while using the Statistical Package for the Social Sciences SPSS. version 20
(SPSS, Chicago, IL, USA).
3. Results
The data of 73 mechanically ventilated medical-surgical ICU patients with tracheal aspirates
that were positive for drug-resistant A. baumannii in the Hospital of Lithuanian University of Health
Sciences Kauno Klinikos during the two-year period were analyzed. A total of 13 cases did not meet
the diagnostic criteria for VAP; therefore, 60 cases were included in the final study. There were 29
(48.3%) women and 31 (51.7%) men with a mean age of 64 (SD 15) years.
3.1. Associations between the VAP Pathogen A.baumannii Drug Resistance Profile and Risk Factors for VAP
MDR, XDR, and pPDR A. baumannii strains caused 13.3%, 68.3%, and 18.3% of all cases regarding
drug-resistant A. baumannii VAP, respectively (p < 0.05). The relationship between the A. baumannii
drug resistance profiles and the risk factors for VAP is presented in Table 1.
The groups of MDR, XDR, and pPDR A. baumannii were homogeneous according to age, gender,
and type of admission (p > 0.05). The majority of patients were admitted due to internal diseases in all
three drug resistance groups: 36.4%—due to pulmonary, 15.2%—due to gastrointestinal, 12.1%—due
to kidney diseases, 12.1%—due to intoxication, and 25.5%—due to miscellaneous internal diseases.
The differences were found in the SAPS II score on ICU admission: the score was the highest in the
pPDR (49, SD 13.5) and the lowest in MDR (42.6, SD 13.8) A. baumannii group (p = 0.048). The hospital
LOS prior to ICU among different drug resistance groups was statistically significantly different as well.
It was the longest in pPDR and the shortest MDR A. baumannii patients (2 days, IQR 0–10 vs. 0 days,
IQR 0–0.75; p = 0.036). The longest hospital LOS before MV was detected in the pPDR A. baumannii
group (3 days, IQR 0–6, p = 0.013). Rates of coma, sepsis, septic shock, chronic diseases, surgery
prior to ICU, tracheostomy, reintubation, hospital LOS and ICU LOS, as well as the duration of MV
prior to VAP development did not differ significantly among the different drug resistance profiles of
A. baumannii (p > 0.05).
No statistically significant association between the duration of antibacterial treatment prior to
VAP and the drug resistance profile of A. baumannii was detected (p = 0.475). The possible relationship
between the MDR, XDR, and pPDR A. baumannii strains and the class of antibiotics used that was
prior to VAP was analyzed. The antibiotics that were used most frequently in all three groups were
cephalosporins and penicillins with or without beta-lactamase inhibitors (BLI). The MDR A. baumannii
group received carbapenems more frequently when compared to the XDR and pPDR groups (50%,
29.3%, and 18.2%, respectively; p = 0.039).
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Table 1. The relationship between MDR, XDR, and pPDR A. baumannii as pathogen of VAP and the
risk factors for VAP.
Variable All Casesn = 60
Drug Resistance Profiles of VAP Pathogen
A. baumannii p Value
MDR n = 8 XDR n = 41 pPDR n = 11
Gender, n (%)
Female 29 (48.3) 6 (75) 18 (43.9) 5 (45.5)
0.201Male 31 (51.7) 2 (25) 23 (56.1) 6 (54.5)
Age (years), mean (SD) 63.95 (15) 60 (18.4) 65.37 (15.3) 61.55 (11.1) 0.555
Reintubation, n (%) 19 (31.7) 3 (37.5) 13 (31.7) 3 (27.3) 0.894
Surgical intervention, n (%) 23 (38.3) 4 (50) 16 (39) 3 (27.3) 0.593
Tracheostomy prior VAP, n (%) 8 (13.3) 0 (0) 5 (12.2) 3 (27.3) 0.209
Severity score on ICU admission:
APACHE II, median (IQR) 19 (13–27.5) 18 (13.3–31.5) 18 (12-24) 23 (18–30) 0.189
SAPS II, mean (SD) 47.95 (13) 42.6 (13.8) 48.7(12.8) 49 (13.5) 0.048
SOFA, mean (SD) 11.5 (4.3) 11.8 (4.3) 11.5 (4.6) 11.36 (3) 0.981
Admission type, n (%)
Surgery 17 (28.3) 2 (25) 10 (24.4) 5 (45.5)
0.186Medical 29 (48.3) 5 (62.5) 18 (43.9) 6 (54.5)
Trauma 14 (23.3) 1 (12.5) 13 (31.7) 0 (0)
Coma (GCS <9), n (%) 8 (13.3) 2 (25.0) 4 (9.8) 2 (18.2) 0.445
Chronic disease, n (%) 43 (71.7) 7 (87.5) 29 (70.7) 7 (63.6) 0.508
Sepsis status on ICU admission, n (%)
Sepsis 54 (90) 8 (100) 36 (87.8) 10 (90.9) 0.572
Shock 20 (33.3) 2 (25) 16 (39) 2 (18.2) 0.371
RBC transfusion prior to VAP, n (%) 36 (60) 4 (50) 24 (58.5) 8 (72.7) 0.573
Antibiotic treatment prior to VAP (days),
median (IQR) 13 (7–18) 10.5 (5.3–13.8) 13 (7.5–20) 14 (6–19) 0.475
Antibiotic treatment prior to VAP (class), n (%)
Cephalosporin 46 (76.7) 5 (62.5) 32 (78) 9 (76.7) 0.576
Penicillin ± BLI 34 (56.7) 3 (37.5) 23 (56.1) 6 (54.5) 0.626
Quinolone 6 (10) 0 (0) 5 (12.2) 1 (9.1) 0.572
Aminoglycoside 3 (5) 1 (12.5) 1 (2.4) 1 (9.1) 0.387
Carbapenem 18 (30) 4 (50) 12 (29.3) 2 (18.2) 0.036
Other 8 (13.3) 1 (12.5) 4 (9.8) 3 (27.3) 0.315
LOS (days), median (IQR)
Hospital prior to ICU 1 (0–3.8) 0 (0–0.8) 1 (0–3.5) 2 (0–10) 0.036
ICU prior to MV 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0.406
ICU prior to VAP 9 (6–13) 9.5 (5.3–13.5) 9 (6–13) 8 (5–16) 0.974
Hospital prior to MV 0 (0–2.7) 0 (0–0) 0 (0–2) 3 (0–6) 0.013
Hospital prior to VAP 11.5(6–16.5) 10 (6–13.5) 12 (6–16) 14 (8–22) 0.424
MV prior to VAP (days), median (IQR) 8.50 (5–14) 10.5 (5–13.3) 8 (5.5–14) 7 (2–11) 0.845
SD—standard deviation, IQR—interquartile range, VAP—ventilator associated pneumonia, ICU—intensive
care unit, APACHE II—Acute Physiology and Chronic Health Evaluation score II, SAPS II—Simplified Acute
Physiology Score, SOFA—Sequential Organ Failure Assessment, GCS—Glasgow coma scale, RBC—red blood cells,
BLI—β-lactamase inhibitors, LOS—length of stay, MV—mechanical ventilation.
3.2. The Relationship between A.baumannii Drug Resistance Profile and Mortality
The in-hospital mortality rate in patients with VAP that was caused by drug-resistant A. baumannii
was 63.3%. The detailed data on in-hospital mortality in MDR, XDR, and pPDR A. baumannii groups
are presented in Figure 1.
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Figure 1. The relationship between A. baumannii drug resistance profile and mortality. Abbreviations:
MDR—multidrug-resistant, XDR—extensively drug-resistant, pPDR—potentially pandrug-resistant,
AcB—A. baumannii, and VAP—ventilator-associated pneumonia.
3.3. Predictors of In-Hospital Mortality
Univariate and multivariate analyses were performed in order to identify the independent
predictors of in-hospital mortality. The in-hospital mortality rate was significantly higher in females
than males (79.3% vs. 48.4%, p < 0.05). The disease severity on ICU admission based on SAPS II
(51.5, SD 10.1) and SOFA (12.7, SD 3.8) scores was also associated with adverse outcomes (p < 0.05).
The higher APACHE II score was observed in non-survivors as compared to survivors, but the
difference was not statistically significant (21.63, SD 9.1 vs. 17.6, SD 7.1, p = 0.082). Non-survivors
had chronic diseases (72.2% vs. 45%, p = 0.038) and RBC transfusions (75% vs. 25%, p = 0.03) more
frequently. The remaining analyzed factors did not differ between the outcome groups. The univariate
analyses of demographic, clinical, and treatment factors are shown in Table 2.
Sensitivity and specificity analyses (ROC curves) were performed in order to assess the ability
of severity scores (SOFA, SAPS II, APACHE II) to predict in-hospital mortality in drug-resistant
A. baumannii VAP patients. The discriminating ability and cut-off of the scores were as follows: AUC
0.73 (95% CI: 0.59–0.86), sensitivity 63.2%, specificity 72.7%, cut-off value 11.5 for SOFA (p = 0.004),
AUC 0.68 (95% CI: 0.54–0.84), sensitivity 68.4%, specificity 63.6%, cut off value 46 for SAPS II (p = 0.016),
and AUC 0.62 (95% CI: 0.54–0.84), sensitivity 68.4%, specificity 50%, and cut-off value 16.5 for APACHE
II (p = 0.118). However, no statistically significant difference was found in the discriminative power
among the scores (p > 0.05). The details are presented in Figure 2.
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Table 2. Univariate analysis of demographics, clinical findings and treatment factors associated with
mortality of drug-resistant A. baumannii VAP patients.
Variable Survivors (n = 22) Non-Survivors (n = 38) p Value
Gender, n (%)
Female 6 (20.7) 23 (79.3)
0.017Male 16 (51.6) 15 (48.4)
Age (years), mean (SD) 60.77 (16) 65.79 (14.3) 0.214
Severity score on ICU admission, mean (SD)
APACHE II 17.64 (7.1) 21.63 (9.1) 0.082
SOFA 9.41 (4.3) 12.71 (3.8) 0.003
SAPS II 41.73 (15.2) 51.55 (10.1) 0.011
Sepsis status on ICU admission, n (%)
Sepsis 19 (35.2) 35 (64.8) 0.659
Shock 9 (45) 11 (55) 0.401
Chronic diseases, n (%) 12 (27.9) 31 (72.1) 0.038
Coma GCS <9, n (%) 4 (50) 4 (50) 0.449
Admission type, n (%)
Surgery 6 (35.3) 11 (64.7)
0.981Internal disease 11 (37.9) 18 (62.1)
Trauma 5 (35.7) 9 (64.3)
Reintubation, n (%) 8 (42.1) 11 (57.9) 0.577
Surgical intervention, n (%) 6 (26.1) 17 (73.9) 0.271
Tracheostomy prior to VAP, n (%) 1 (12.5) 7 (87.5) 0.238
RBC transfusion prior to VAP, n (%) 9 (25) 27 (75) 0.03
RBC (units), median (IQR) 0 (0–2.3) 2 (0–5) 0.044
LOS (days), median (IQR)
Hospital prior to ICU 0.5 (0–3.5) 1 (0–4) 0.568
ICU prior to MV 0 (0–0.3) 0 (0–0.25) 0.876
ICU prior to VAP 8 (5.8–11) 9.5 (5.8–15) 0.442
Hospital prior to MV 0 (0–1.3) 0.5 (0–4) 0.341
Hospital prior to VAP 9.5 (6–14) 13 (7.5–20) 0.126
MV prior to VAP (days), median (IQR) 9 (5–11.5) 8 (5–15.3) 0.729
Antibiotic treatment prior to VAP (days),
median (IQR) 10 (6–14.8) 14 (7.8–20) 0.164
SD—standard deviation, IQR—interquartile range, ICU—intensive care unit, APACHE II—Acute Physiology and
Chronic Health Evaluation score II, SAPS II—Simplified Acute Physiology Score II, SOFA—Sequential Organ Failure
Assessment score, GCS—Glasgow coma scale, RBC—red blood cells, BLI—β-lactamase inhibitors, LOS—length of
stay, MV—mechanical ventilation, and VAP—ventilator associated pneumonia.
The stepwise backward binary logistic regression was used to determine the independent
predictors of in-hospital mortality. The following variables were included: gender, disease severity
score on ICU admission (SOFA, SAPS II scores), presence of chronic diseases, and RBC transfusion
prior to the diagnosis of VAP. The independent predictors of in-hospital mortality in VAP due to
drug-resistant A. baumannii patients were female gender, SOFA score on ICU admission, and the RBC
transfusion prior to VAP. The details are presented in Table 3.
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Antibiotic treatment prior to VAP (days), median 
(IQR) 
10 (6–14.8) 14 (7.8–20) 0.164 
SD—standard deviation, IQR—interquartile range, ICU—intensive care unit, APACHE II—Acute 
Physiology and Chronic Health Evaluation score II, SAPS II—Simplified Acute Physiology Score II, 
SOFA—Sequential Organ Failure Assessment score, GCS—Glasgow coma scale, RBC—red blood 
cells, BLI—β-lactamase inhibitors, LOS—length of stay, MV—mechanical ventilation, and VAP—
ventilator associated pneumonia. 
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Figure 2. Receiver operating characteristic (ROC) curves for predicting in-hospital mort lity according
t Simplified Acute Physiology Sc re (SAPS II), cute Physiology and Chronic Health Evaluation
(APACHE) II, and Sequential Organ Failure Assessment (SOFA) scores at intensive care unit
(ICU) admission.
Table 3. Independent predictors of in-hospital mortality of drug-resistant A. baumannii VAP patients.
Independent Variable Odds Ratio 95% CI p Value
Gender (female) 5.26 1.21–22.83 0.027
SOFA score on ICU
admission 1.28 1.06–1.53 0.008
RBC transfusion 5.97 1.41–25.27 0.015
CI—confidence interval, SOFA—Sequential Organ Failure Assessment score, ICU—intensive care unit, RBC—red
blood cell transfusion.
4. Discussion
VAP risk factors: disease severity on admission to ICU (SAPS II score), longer hospital LOS
prior to ICU, and prior to MV have been associated with higher drug resistance of A. baumannii.
The previous use of carbapenems was associated with the risk of the development of MDR A. baumannii
VAP. The overall in-hospital mortality rate was high (63.3%), but the influence of A. baumannii drug
resistance profile on mortality was not significant. The female sex, the SOFA score on ICU admission,
and the need for RBC transfusion were found to be independent predictors for mortality.
The MDR, XDR, and pPDR A. baumannii VAP patient groups were homogenous for demographic,
anamnestic, and clinical data on the admission to ICU. According to previous studies, the main risk
factors for VAP due to A. baumannii were antibiotic therapy (especially of the broad spectrum), MV,
hospital LOS, invasive procedures, disease severity, and the presence of chronic diseases [2,3,19].
In Inchai et al. [19] study, carbapenem treatment was associated with the risk of VAP due to all three
types of A. baumannii drug-resistance profiles, in particular PDR, and odds ratio for MDR, XDR, and
PDR A. baumannii VAP were 5.2, 6.3, and 12.84, respectively. Carbapenems use was also found to
be a risk factor for XDR A. baumannii VAP in Li et al. study [3]. The risk factor for VAP due to PDR
A. baumannii was previous colistin treatment as well [19]. We observed more frequent carbapenem
use prior to VAP in MDR A. baumannii group (p = 0.036), as in Inchai et al. study [19], missing the
association with XDR and pPDR due to an insufficient study population. We only investigated the
relation between the drug resistance profile of A. baumannii as a VAP pathogen and the established
risk factors for VAP. Although it would be worthwhile to identify the risk factors for VAP due to
A. baumannii of separate drug resistance profiles by logistic regression analysis; however, significant
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prevailing of XDR strains came out with too small sample sizes in MDR and pPDR profiles to allow for
this analysis to be performed.
Another risk factor for drug-resistant A. baumannii VAP is disease severity estimated by SAPS II,
APACHE II, and SOFA scores [2,3,19]. More severely ill patients tend to develop VAP due to the more
resistant (XDR or PDR) A. baumannii strain [23]. Evidently, incoherence in opinion exists regarding
the relation of predictive values of severity scores with the drug resistance profile of A. baumannii.
Inchai et al. [19] found that a higher SOFA score predicted XDR and the higher SAPS II score—PDR
A. baumannii VAP. In the study by Ozgur et al. [2], a higher SAPS II score predicted the risk of
XDR-A. baumannii VAP; however, Li et al. [3] demonstrated that the APACHE II score had the best
predictive ability. According to our results, only the SAPS II score was found to be statistically
significantly associated with the higher drug resistance of the A. baumannii strain (p = 0.048).
The ICU LOS prior to MV, prior to VAP, and hospital LOS prior to VAP did not differ among
the A. baumannii drug resistance groups. However, we found that patients in the pPDR A. baumannii
group in comparison with the MDR and XDR groups had longer hospital LOS prior to ICU (p = 0.036)
and prior to MV (p = 0.013). Unlike our study, Ozgur et al. [2] indicated that longer hospital LOS
was a statistically significant risk factor of XDR A. baumannii VAP. We did not analyze the relation of
the hospital and the ICU LOS with different A. baumannii drug resistance profiles, as we think that,
methodologically, it would be more accurate to investigate LOS prior to VAP as a possible risk factor
for VAP. From our point of view, the LOS after the diagnosis of VAP as a component of the general
hospital LOS is more reflective of the effectiveness of treatment and patient outcome. In addition, it
may be related not only to the disease severity, but also to the prevailing drug resistance mechanisms
in different hospitals or departments.
Finally, no differences among the various A. baumannii drug resistance profiles with regard to the
duration of antibiotic therapy prior to VAP, the type of admission, sepsis, coma, tracheostomy, surgery,
RBC transfusion, and reintubation rates were detected. In a sample case control study by Li et al. that
was smaller than ours [3], COPD and heart disease were identified as risk factors for XDR A. baumannii
VAP (p < 0.05). Unlike Li et al. [3], we only analyzed the presence of chronic diseases, but not isolated
pathologies, and we did not identify the relation of it in general (p = 0.508).
Eventually, an in-hospital mortality rate of VAP due to A. baumannii is high, and according
to Ozgur et al. [2] study can reach up to 85.3% in the cases of XDR A. baumannii VAP. However,
the pathogen drug resistance has not been proven to influence mortality, because of this study did
not clarify what the resistance profiles the non-XDR group consist of. The in-hospital mortality in
our study was found to be 63.3%, which is comparable with other studies [23,24]. Actually, we
expected in-hospital mortality to increase with the higher drug resistance of A. baumannii. Despite the
higher mortality rate in pPDR A. baumannii VAP group (72.7%), this difference was not statistically
significant (p = 0.77). Our results are consistent with those of Ozgur et al. [2], Li et al. [3], and
Inchai et al. [23], where the higher mortality rate in more drug-resistant A. baumannii VAP patients
also was not statistically significant. The current opinion states that the higher mortality rate in VAP
due to drug-resistant pathogens is associated with concomitant illnesses and the disease severity in the
presence of VAP, but not with the only VAP itself or specifically the drug resistance of A. baumannii.
Age, concomitant diseases, invasive treatment or monitoring methods, inappropriate antibacterial
therapy, septic shock, and the severity of illness are proven as the prognostic factors for drug-resistant
A. baumannii VAP patients’ mortality [2,3,5,23]. We could not analyze the mortality factors for each
separate A. baumannii drug resistance profile due to an insufficient number of cases in the MDR and
pPDR groups; therefore, we have only investigated the whole study population. So far, we have found
the female gender, SOFA score on admission to ICU, and RBC transfusion to be independent predictors
for mortality in VAP, due drug-resistant A. baumannii.
Currently, in addition to identifying individual prognostic factors, the prognostic accuracy of
various prognostic models is being investigated. The data on the predictive ability of prognostic
scores remain controversial. One of the most recent meta-analysis by Larsson et al. [25] examined the
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accuracy of the seven mortality predictive models (APACHE II, CPIS, Immunodeficiency, IBMP-10,
VAP PIRO, SOFA, SAPS II, and APACHE III), which have been used in patients with VAP. All of
the models had almost equal pooled predictive ability, with the range of AUC being from 0.64 to
0.72. APACHE II, SAPS II, and SOFA were used most frequently in the included studies. APACHE II
showed the highest overall predictive ability (AUC 0.72). However, the studies that were included
in the meta-analysis did not distinguish the subgroup of patients with VAP due to drug-resistant
A. baumannii; therefore, it is unclear whether the results could be applied to them. Our results differ
from those of Larsson et al. [25], as the APACHE II score on ICU admission did not differ significantly
between the survivors and non-survivors in our study, but comprehensibly the SOFA and SAPS II
scores were statistically significantly higher in the non-survivors group (p < 0.05). In addition, the
higher SOFA score on ICU admission predicted in-hospital mortality in the multivariate analysis
(OR 1.28, 95% CI: 1.06–1.53). Although the SOFA score was the least sensitive (63.2%) when compared
to APACHE II and SAPS II, it has had the highest specificity (72.7%). Based on the AUC of the ROC
curve, the discriminatory ability of the SOFA score was good (AUC 0.73). In contrast to Larson et al.
meta-analysis [25], both APACHE II and SAPS II had poor discriminatory ability (AUC 0.62 and 0.68,
respectively). Likewise to our study, Karakuzu et al. [26] also noticed a better discriminative ability
of the SOFA score when compared to the APACHE II (AUC 0.82 vs. 0.62), but for A. baumannii, there
was just less than the half of the examined pathogens and their resistance was not specified, as our
study did, which eventually confirms the strongest significance of our study findings. Comparably,
Inchai et al. [23] also found that the SOFA score on the VAP diagnosis day and, in contrast to our study,
by the SAPS II score, statistically significantly predicted the XDR A. baumannii VAP patient mortality.
In our opinion, the SAPS II score is also related to demographic and anamnesis data, which are
supporting less correlation in the severity of VAP than clinical presentation in SOFA score. The relation
between the APACHE II score and the drug-resistant A. baumannii VAP patients’ mortality rate was
also confirmed by Tsioutis et al. [27] study, which differs from Karakuzu et al. [26], Inchai et al. [23], and
our study. This is why conclusion regarding the accuracy of some scores has been not estimated yet.
In literature, data on gender interrelation with mortality varies: it is indicated that either
mortality is higher in men, or gender has no significant influence in drug-resistant A. baumannii
VAP patients [23,24], but in our study, female sex has a significantly higher death rate than men (79.3%
vs. 48.2%, p = 0.017); also, it was an independent predictor for in-hospital mortality (OR 5.26, 95% CI:
1.21-22.83). Subsequently, in order to explain this gender and mortality interrelation, we compared
the characteristics of the men and women subgroups. Women have been older than men (66.8 vs.
61.2 years, p = 0.035), and they more often have had at least one chronic disease (82.8% vs. 61.3%,
p = 0.065). Similar to our results, Tsioutis et al. [27] has found higher mortality rate in females too, but
only in a univariate analysis.
We found that RBC transfusion predicted in-hospital mortality in patients with drug-resistant
A. baumannii VAP. Currently, no research has been performed regarding the linkage between the
RBC transfusion and mortality in VAP patients. Data on mortality in other patient populations
are controversial. In the systematic review of 46 observational studies, which has investigated
the impact of blood transfusions on outcome in heterogeneous patient groups (trauma, general,
cardiac and neurosurgery, orthopedic, cardiac, and general ICU), Marik et al. [28] found that RBC
transfusion independently predicted death (pooled OR from 12 studies 1.7; 95% CI: 1.4–1.9), infectious
complications (pooled OR from nine studies 1.8; 95% CI: 1.5–2.2), and ARDS (pooled OR from six
studies 2.5; 95% CI: 1.6–3.3). In ICU patients, the three trials that were included in the review confirmed
a statistically significant association between RBC transfusion and mortality. However, the SOAP
study that was conducted in 198 European ICUs not only failed to detect association between RBC
transfusion and higher mortality but it found that patients who received transfusion had a better
survival [29]. Most recent post-hoc analysis of the multicenter, worldwide audit database of 9553 RBC
transfused critically ill patients found that transfusions were associated with slightly lower relative-risk
for in-hospital death in the most severely ill patients [30]. It is assumed that a worse outcome of patients
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being transfused is determined not only by the increased risk of infection, but also by non-infectious
transfusion-related complications (immunomodulation, acute lung injury, circulatory overload) and
RBC storage lesion [29]. These detrimental effects may be further enhanced in sepsis patients, in which
sepsis-induced microcirculation impairment develops [29].
Advantages and limitations of the study. The main advantage despite the relatively small sample
of study was, to our knowledge, being the very first study that included mixed a medical-surgical
ICU population, not only in the biggest academical hospital of Lithuania, but also in Baltic States
and Eastern Europe. The limitations of the study are as follows: this is a single-center ICU study in
adults; in addition, the A. baumannii strains were not routinely tested for sensitivity to colistin until
mid-2015, which means that some strains could be attributed to a potentially higher drug resistance
category, despite their sensitivity to colistin. Additionally, we analyzed patient’s data only on ICU
admission; however, patient’s condition on both the onset of VAP and on the forthcoming days could
be an important prognostic factor. In order to be more precise on the results reflecting the situation in
the different countries and hospitals, larger multicenter studies would be relevant. Such studies would
allow for a better understanding of the impact of drug-resistant A. baumannii as a causative agent for
VAP on in-hospital mortality.
5. Conclusions
Accordingly, the higher the SAPS II score, increased durations of hospital length of stay prior to
ICU and prior to mechanical ventilation were related to higher resistance profiles of A. baumannii, timely
mechanical ventilation, and ICU treatment may reduce the risk of VAP due to higher drug-resistant
A. baumannii, especially in more severely ill patients. Carbapenem use has been shown to be associated
with the risk of MDR A. baumannii VAP. Mortality that is due to drug-resistant A. baumannii VAP
was high, but it has not been significantly associated with higher drug resistance of the A. baumannii
strain. Female gender, SOFA score, and RBC transfusion were found to be independent predictors
of in-hospital mortality. For instance, the estimation of red blood cells transfusion as independent
predictor of in-hospital mortality allows for clinicians to be more responsible in consideration of
the use RBC packs without obvious tissue hypoxia signs in purpose to preserve optimal survival.
In our opinion, this investigation gives opportunities for clinicians regarding a better understanding
of suspect VAP due to drug-resistant A. baumannii by risk factors, which are significantly associated
with the drug resistance of pathogen, so as to enable easier prevention of VAP infection and mortality
control. Obviously, our presented information makes it possible to predict mortality, to influence
strategy of treatment, and to be able to decrease the higher costs of healthcare in this contingent of
patients. We do suggest that researchers of other countries join our study for the investigation of the
relation of risk factors for VAP and mortality with resistance profiles of the A. baumannii strain, and
the estimation of the independent predictors of in-hospital mortality, which are the most important
clinical issues in critical care nowadays.
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